Bifogade filer
Ascelia Pharma Q2 2024 EN 240815
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ascelia Pharma AB (publ) (ticker: ACE) today published its Half-Year Report for 2024 (January – June), which is now available on the company’s website: https://www.ascelia.com/ir-media/financial-reports/
KEY EVENTS IN Q2 2024
- SPARKLE image reading completed with expected headline results first half of May 2024
- Ascelia Pharma draws down SEK 15 million second tranche under existing loan facility
- Primary endpoint successfully met with strong headline results in Orviglance® phase 3 study
- Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024
- Ascelia Pharma hosts Investor Update: Bringing Orviglance to Patients
KEY EVENTS AFTER THE PERIOD
- Ascelia Pharma carries out a Rights Issue of units of approximately SEK 105 million to fully finance the NDA submission for Orviglance
- Notice of Extraordinary General Meeting in Ascelia Pharma 14 August
- Bulletin from the Extraordinary General Meeting in Ascelia Pharma 14 August
FINANCIAL SUMMARY Q2 (Apr-Jun) 2024
- Operating result of SEK -11.3M (SEK -41.8M)
- Earnings per share of SEK -0.39 (SEK -1.19)
- Cash flow from operations of SEK -12.0M (SEK -42.3M)
- Liquid assets and marketable securities of SEK 29.8M (SEK 70.5M)
“In May 2024, we announced strong positive headline results from our pivotal Phase 3 study, SPARKLE, with Orviglance. The results showed that Orviglance significantly improved the visualization of focal liver lesions, successfully meeting the primary endpoint with statistical significance for all three readers (<0.001).
The successful Phase 3 data reinforce our confidence in the regulatory and commercial path ahead for Orviglance and mark the completion of clinical development for Orviglance. We will now focus on bringing Orviglance through the regulatory submission and approval process with a submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) expected by mid 2025. We also continue to advance the dialogue with potential commercialization partners to launch Orviglance and make it available to patients who need high-quality liver imaging without gadolinium-related safety risk.
On 10 July, we announced the launch of a rights issue of approximately SEK 105 million, secured to SEK 70 million. This financing improves our financial position and strengthens our ability to obtain an attractive agreement with commercialization partners. It also ensures that we can complete all activities for the NDA submission mid 2025 with high quality. I am pleased that the financing allows all our shareholders to take part in the significant value creation opportunities ahead.”, said Magnus Corfitzen, CEO at Ascelia Pharma.
A presentation for analysts, investors and media will be held today 15 August at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, Deputy CEO Julie Waras Brogren, and CSO Andreas Norlin. The presentation will be held in English. The presentation can be followed live via the link:
Ascelia Pharma Q2 Report 2024 (financialhearings.com)
To participate via teleconference, please register through the link below. After registration, you will be provided with phone numbers and a conference ID to access the conference.
Call Access (financialhearings.com)
It will also be possible to access the audiocast afterwards at the same address or on the website of Ascelia Pharma: https://www.ascelia.com/ir-media/